Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1

Journal of Pathology

Volumn 230, Issue 2, 2013, Pages 184-193

  Han, Yu Chen ^a   Zheng, Zhong Liang ^a   Zuo, Ze Hua ^a   Yu, Yan P ^a   Chen, Rui ^b   Tseng, George C ^b   Nelson, Joel B ^a   Luo, Jian Hua ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

histone methylation; metallothionein; prostate cancer; suppression; tumour

Indexed keywords

EUCHROMATIN HISTONE METHYLTRANSFERASE 1; HISTONE H3; METALLOTHIONEIN; METALLOTHIONEIN IH; METHYLTRANSFERASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; BLADDER CANCER; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; CHORIOCARCINOMA; CHRONIC MYELOID LEUKEMIA; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DEMETHYLATION; DOWN REGULATION; EMBRYONAL RHABDOMYOSARCOMA; ENZYME ACTIVITY; EWING SARCOMA; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HISTONE METHYLATION; HUMAN; IN VITRO STUDY; LARGE CELL LYMPHOMA; LUNG SMALL CELL CANCER; M PHASE CELL CYCLE CHECKPOINT; MALE; MELANOMA; METASTASIS; MULTIPLE MYELOMA; MYELOID LEUKEMIA; MYELOMA; NEUROBLASTOMA; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; SYNOVIAL SARCOMA;

ADENOCARCINOMA; ANIMALS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LIVER NEOPLASMS; MALE; METALLOTHIONEIN; MICE; MICE, SCID; MICROARRAY ANALYSIS; PENNSYLVANIA; PROSTATIC NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84877737760     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4169     Document Type: Article

References (23)

1. Webb M., Functions of hepatic and renal metallothioneins in the control of the metabolism of cadmium and certain other bivalent cations. Experientia 1979; 34: 313-320.
2. Webb M, Cain K,. Functions of metallothionein. Biochem Pharmacol 1982; 31: 137-142.
3. Fowler BA, Hildebrand CE, Kojima Y, et al,. Nomenclature of metallothionein. Experientia 1987; 52: 19-22.
4. Porter H., The particulate half-cystine-rich copper protein of newborn liver. Relationship to metallothionein and subcellular localization in non-mitochondrial particles possibly representing heavy lysosomes. Biochem Biophys Res Commun 1974; 56: 661-668.
5. Cherian MG, Clarkson TW,. Biochemical changes in rat kidney on exposure to elemental mercury vapor: effect on biosynthesis of metallothionein. Chem Biol Interact 1976; 12: 109-120.
6. Lukk M, Kapushesky M, Nikkila J, et al,. A global map of human gene expression. Nature Biotechnol 2010; 28: 322-324.
7. Cherian MG, Jayasurya A, Bay BH,. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003; 533: 201-209.
8. Ogawa H, Ishiguro K, Gaubatz S, et al,. A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science 2002; 296: 1132-1136.
9. Jing L, Liu L, Yu YP, et al,. Expression of myopodin induces suppression of tumor growth and metastasis. Am J Pathol 2004; 164: 1799-1806.
10. Ren B, Yu YP, Tseng GC, et al,. Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J of the National Cancer Institute 2007; 99: 868-80.
11. Ren B, Yu G, Tseng GC, et al,. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 2006; 25: 1090-8.
12. Yu G, Tseng GC, Yu YP, et al,. CSR1 suppresses tumor growth and metastasis of prostate cancer. Am J Pathol 2006; 168: 597-607.
13. Yu YP, Yu G, Tseng G, et al,. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res 2007; 67: 8043-8050.
14. Yu YP, Landsittel D, Jing L, et al,. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22: 2790-2799.
15. Luo JH, Ren B, Keryanov S, et al,. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 2006; 44: 1012-1024.
16. Yu YP, Song C, Tseng G, et al,. Genome abnormalities precede prostate cancer and predict clinical relapse. Am J Pathol 2012; 180: 2240-2248.
17. Nalesnik MA, Tseng G, Ding Y, et al,. Gene deletions and amplifications in human hepatocellular carcinomas: correlation with hepatocyte growth regulation. Am J Pathol 2012; 180: 1495-1508.
18. McGraw S, Vigneault C, Sirard MA,. Temporal expression of factors involved in chromatin remodeling and in gene regulation during early bovine in vitro embryo development. Reproduction 2007; 133: 597-608.
19. Akbarian S, Huang HS,. Epigenetic regulation in human brain-focus on histone lysine methylation. Biol Psychiatry 2009; 65: 198-203.
20. Wong VV, Nissom PM, Sim SL, et al,. Zinc as an insulin replacement in hybridoma cultures. Biotechnol Bioeng 2006; 93: 553-563.
21. Tang X, Shay NF,. Zinc has an insulin-like effect on glucose transport mediated by phosphoinositol-3-kinase and Akt in 3 T3-L1 fibroblasts and adipocytes. J Nutr 2001; 131: 1414-1420.
22. Roussel AM, Kerkeni A, Zouari N, et al,. Antioxidant effects of zinc supplementation in Tunisians with type 2 diabetes mellitus. J Am Coll Nutr 2003; 22: 316-321.
23. Schott-Ohly P, Lgssiar A, Partke HJ, et al,. Prevention of spontaneous and experimentally induced diabetes in mice with zinc sulfate-enriched drinking water is associated with activation and reduction of NF-kappa B and AP-1 in islets, respectively. Exp Biol Med 2004; 229: 1177-1185.